Medical research

INTEGRATED ONCOLOGY NETWORK and cCARE WELCOME HEMATOLOGY ONCOLOGIST DR. PHILIP MARJON TO THEIR MEDICAL TEAM

Retrieved on: 
Thursday, February 8, 2024

NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the addition of distinguished Hematology Oncologist Dr. Philip Marjon to the medical team. 

Key Points: 
  • NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- Integrated Oncology Network (ION), with California Cancer Associates for Research & Excellence (cCARE) is thrilled to announce the addition of distinguished Hematology Oncologist Dr. Philip Marjon to the medical team.
  • We are excited to expand our team of expert medical professionals and enhance oncology care and support to our patients.
  • Philip Marjon, M.D., M.S., is a board-certified Hematologist and Medical Oncologist, having earned his medical degree from the University of New Mexico School of Medicine.
  • Dr. Marjon began his medical career as part of a research team with the University of New Mexico's Department of Biochemistry.

Feinstein Institutes research shows that psychiatric disorders are linked to dementia not through genetics, but alcohol use as shared cause

Retrieved on: 
Tuesday, February 6, 2024

While psychiatric disorders have previously been evaluated as a predictor for dementia, a new study from researchers at The Feinstein Institutes for Medical Research provides evidence that psychiatric disorders before dementia onset are not connected to genetic dementia risks.

Key Points: 
  • While psychiatric disorders have previously been evaluated as a predictor for dementia, a new study from researchers at The Feinstein Institutes for Medical Research provides evidence that psychiatric disorders before dementia onset are not connected to genetic dementia risks.
  • “This research has helped us to recognize that alcohol use disorder greatly increases the chances of both psychiatric disorders and subsequent dementia.
  • This paves the way for future research to better inform interventions and care.”
    The study investigated the relationship between psychiatric disorders and known genetic risks of dementia.
  • The researchers conclude that shared risk factors may account for a large part of the association between psychiatric disorders and dementia, like alcohol use disorder that is a shared risk of both PDPD and dementia.

Pixelgen Technologies and Australian Biosearch Announce Distribution Agreement

Retrieved on: 
Tuesday, February 6, 2024

STOCKHOLM and WANGARA, Australia, Feb. 6, 2024 /PRNewswire/ -- Pixelgen Technologies® announced today a non-exclusive agreement with leading distributor Australian Biosearch. The partnership will bring Pixelgen's Molecular Pixelation (MPX) kits for high-multiplex spatial analysis of membrane proteins to the Australian and New Zealand markets. 

Key Points: 
  • STOCKHOLM and WANGARA, Australia, Feb. 6, 2024 /PRNewswire/ -- Pixelgen Technologies ® announced today a non-exclusive agreement with leading distributor Australian Biosearch .
  • The partnership will bring Pixelgen's Molecular Pixelation (MPX) kits for high-multiplex spatial analysis of membrane proteins to the Australian and New Zealand markets.
  • "The Australasian biotech market is rapidly growing, and this agreement will help ensure our products reach this important region as we expand globally."
  • Earlier this month, Pixelgen announced a distribution agreement for Japan and launched a sales team in the U.S. with a new global sales position in Boston.

Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

Retrieved on: 
Thursday, February 1, 2024

Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.

Key Points: 
  • Arndt has extensive experience in discovery, project and portfolio management, preclinical and clinical development, FDA negotiations and regulatory filings as well as business development.
  • Eva-Lotta Allan, Chair of the Board of Directors commented: "It is with great pleasure that I, on behalf of the Board, welcome Arndt to Maxion.
  • Dr Arndt Schottelius, incoming CEO said: "Maxion's truly revolutionary technology has the unique opportunity to deliver first-in-class and best-in-class protein therapeutics to treat ion channel and GPCR-driven diseases.
  • I am delighted to join Maxion Therapeutics at such an exciting time in the Company's development.

Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors

Retrieved on: 
Thursday, January 25, 2024

Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.

Key Points: 
  • Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer.
  • Federico brings over 25 years of experience in gene therapy, immunology, as well as biochemistry and molecular biology in academia and industry.
  • Federico has participated in numerous clinical trials targeting metabolic and neuromuscular diseases, hereditary blindness, and coagulation disorders.
  • Khalil Barrage, ad interim Chair of Sensorion's Board of Directors, said: "We are delighted to welcome Federico Mingozzi as new director.

ZOLL Foundation Marks Ten Years of Providing “Seed” Grants to Young Medical Researchers Around the World

Retrieved on: 
Tuesday, January 23, 2024

To date, the ZOLL Foundation has awarded more than $6 million in grants to 150 individuals and their respective institutions in 20 countries on six continents.

Key Points: 
  • To date, the ZOLL Foundation has awarded more than $6 million in grants to 150 individuals and their respective institutions in 20 countries on six continents.
  • Now in its tenth year, the ZOLL Foundation expects its total awards to exceed $7 million in 2024.
  • “The ZOLL Foundation’s vision is that our seed grants will support follow-on research that improves care and enhances training in clinical practice,” said Ward Hamilton, President of the ZOLL Foundation Board of Directors.
  • Early support by the ZOLL Foundation was incredibly valuable for me as an investigator.

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Retrieved on: 
Monday, January 22, 2024

PLYMOUTH MEETING, Pa., Jan. 22, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopkins University and a Principal Investigator in INOVIO's Phase 1/2 trial with INO-3107.

Key Points: 
  • The fireside chat, titled "RRP - Disease Treatment Dynamics & Urgent Need for Therapeutic Modalities," will take place on Wednesday, January 24, 2024, at 12:00pm ET.
  • Hartaj Singh, MBA, Managing Director of Biotechnology Equity Research at Oppenheimer & Co. Inc., will moderate the discussion.
  • He is a fellowship-trained laryngeal surgeon whose clinical interests are focused on voice and airway disorders, with a particular interest in RRP.
  • Prior to joining INOVIO, she was the CEO at Aeras, a not-for-profit organization dedicated to developing new vaccines against tuberculosis (TB).

13 Mercy Medical Center Physicians Named Among Castle Connolly's "TOP DOCTORS" in 2024

Retrieved on: 
Friday, January 19, 2024

"Mercy providers continue to garner recognition for their skills and achievement in patient care." -- Dr. David N. Maine, President and CEO, Mercy Health Services

Key Points: 
  • -- Dr. David N. Maine, President and CEO, Mercy Health Services
    This marks the third consecutive year that this slate of Mercy physicians have been recognized by Castle Connolly.
  • "Mercy providers continue to garner recognition for their skills and achievement in patient care.
  • The Castle Connolly awards are more evidence of Mercy's commitment to providing quality care, delivered in a compassionate setting," said Dr. David N. Maine, President and CEO, Mercy Health Services, Mercy Medical Center.
  • Founded in 1874 in downtown Baltimore, MD, by the Sisters of Mercy, Mercy Medical Center is a 179-licensed bed acute care university-affiliated teaching hospital.

PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions

Retrieved on: 
Monday, January 15, 2024

MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.

Key Points: 
  • MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit.
  • Nanobind kits are designed for researchers to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types.
  • These kits are versatile, accommodating both manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) settings.
  • "The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing," said Jeff Eidel, Chief Commercial Officer at PacBio.

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Retrieved on: 
Thursday, January 11, 2024

This is in contrast to other KRAS-targeted therapeutics in development — particularly small molecule KRAS inhibitors — which target fewer mutations, potentially limiting the number of patients that can be treated and also limiting duration of benefit due to development of escape mutants.

Key Points: 
  • This is in contrast to other KRAS-targeted therapeutics in development — particularly small molecule KRAS inhibitors — which target fewer mutations, potentially limiting the number of patients that can be treated and also limiting duration of benefit due to development of escape mutants.
  • “ELI-002 represents a cancer vaccine approach that could potentially address the much broader spectrum of pancreatic cancer KRAS mutations.
  • The Phase 2 study builds on positive findings from our 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating a significantly improved decrease in tumor biomarkers, along with strong T cell responses that correlated with a reduced risk of relapse and death.
  • Initial interim data on ELI-002 7P monotherapy from Phase 1A arm will be shared in the first half of 2024.